Page 8 - Probe Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(1) TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium - 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendoc...

POINT Biopharma POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177...

MONTREAL/TORONTO (REUTERS) - Medical companies and shippers in Canada are racing to transport time-sensitive radiochemical materials used to treat cancer, as a pandemic-induced drop in passenger flights has narrowed transportation options and created cargo delays. Half of air cargo normally travels in the belly of passenger jets rather than dedicated freighters. But flight cancellations as traffic plummeted during the pandemic have left some companies scrambling to ship treatments that decay over time, pushing up overall transportation costs. Before the pandemic, the McMaster Nuclear Reactor ...

Medical companies and shippers in Canada are racing to transport time-sensitive radiochemical materials used to treat cancer, as a pandemic-induced drop in passenger flights has narrowed transportation options and created cargo delays.

  MONTREAL/TORONTO -- Medical companies and shippers in Canada are racing to transport time-sensitive radiochemical materials used to treat cancer, as a pandemic-induced drop in passenger flights has narrowed transportation options and created cargo delays. Half of air cargo normally travels in the belly of passenger jets rather than dedicated freighters. But flight cancellations as traffic plummeted during the pandemic have left some companies scrambling to ship treatments that decay over time, pushing up overall transportation costs. Before the pandemic, the McMaster Nuclear Reactor in...